BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37535134)

  • 1. Prospective use of molecular minimal residual disease for risk stratification in children and adolescents with acute lymphoblastic leukemia : Long-term results of the AIEOP-BFM ALL 2000 trial in Austria.
    Ronceray L; Dworzak M; Dieckmann K; Ebetsberger-Dachs G; Glogova E; Haas OA; Jones N; Nebral K; Moser R; Lion T; Meister B; Panzer-Grümayer R; Strehl S; Peters C; Pötschger U; Urban C; Mann G; Attarbaschi A;
    Wien Klin Wochenschr; 2023 Aug; ():. PubMed ID: 37535134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study.
    Conter V; Bartram CR; Valsecchi MG; Schrauder A; Panzer-Grümayer R; Möricke A; Aricò M; Zimmermann M; Mann G; De Rossi G; Stanulla M; Locatelli F; Basso G; Niggli F; Barisone E; Henze G; Ludwig WD; Haas OA; Cazzaniga G; Koehler R; Silvestri D; Bradtke J; Parasole R; Beier R; van Dongen JJ; Biondi A; Schrappe M
    Blood; 2010 Apr; 115(16):3206-14. PubMed ID: 20154213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis.
    Conter V; Valsecchi MG; Buldini B; Parasole R; Locatelli F; Colombini A; Rizzari C; Putti MC; Barisone E; Lo Nigro L; Santoro N; Ziino O; Pession A; Testi AM; Micalizzi C; Casale F; Pierani P; Cesaro S; Cellini M; Silvestri D; Cazzaniga G; Biondi A; Basso G
    Lancet Haematol; 2016 Feb; 3(2):e80-6. PubMed ID: 26853647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster groups.
    Conter V; Schrappe M; Aricó M; Reiter A; Rizzari C; Dördelmann M; Valsecchi MG; Zimmermann M; Ludwig WD; Basso G; Masera G; Riehm H
    J Clin Oncol; 1997 Aug; 15(8):2786-91. PubMed ID: 9256120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11): a nationwide, multicenter, phase 2 trial including randomisation in the very high-risk group.
    Sato A; Hatta Y; Imai C; Oshima K; Okamoto Y; Deguchi T; Hashii Y; Fukushima T; Hori T; Kiyokawa N; Kato M; Saito S; Anami K; Sakamoto T; Kosaka Y; Suenobu S; Imamura T; Kada A; Saito AM; Manabe A; Kiyoi H; Matsumura I; Koh K; Watanabe A; Miyazaki Y; Horibe K
    Lancet Haematol; 2023 Jun; 10(6):e419-e432. PubMed ID: 37167992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
    Basso G; Veltroni M; Valsecchi MG; Dworzak MN; Ratei R; Silvestri D; Benetello A; Buldini B; Maglia O; Masera G; Conter V; Arico M; Biondi A; Gaipa G
    J Clin Oncol; 2009 Nov; 27(31):5168-74. PubMed ID: 19805690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica.
    Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi AM; Messina C; Mori PG; Miniero R; Colella R; Basso G
    J Clin Oncol; 1995 Oct; 13(10):2497-502. PubMed ID: 7595699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster Study Group.
    Borkhardt A; Cazzaniga G; Viehmann S; Valsecchi MG; Ludwig WD; Burci L; Mangioni S; Schrappe M; Riehm H; Lampert F; Basso G; Masera G; Harbott J; Biondi A
    Blood; 1997 Jul; 90(2):571-7. PubMed ID: 9226156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
    Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
    J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IKZF1
    Stanulla M; Dagdan E; Zaliova M; Möricke A; Palmi C; Cazzaniga G; Eckert C; Te Kronnie G; Bourquin JP; Bornhauser B; Koehler R; Bartram CR; Ludwig WD; Bleckmann K; Groeneveld-Krentz S; Schewe D; Junk SV; Hinze L; Klein N; Kratz CP; Biondi A; Borkhardt A; Kulozik A; Muckenthaler MU; Basso G; Valsecchi MG; Izraeli S; Petersen BS; Franke A; Dörge P; Steinemann D; Haas OA; Panzer-Grümayer R; Cavé H; Houlston RS; Cario G; Schrappe M; Zimmermann M; ;
    J Clin Oncol; 2018 Apr; 36(12):1240-1249. PubMed ID: 29498923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment results of childhood acute lymphoblastic leukemia in Austria--a report of 20 years' experience.
    Attarbaschi A; Mann G; Dworzak M; Urban C; Fink FM; Dieckmann K; Riehm H; Gadner H;
    Wien Klin Wochenschr; 2002 Feb; 114(4):148-57. PubMed ID: 12060981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia.
    Flohr T; Schrauder A; Cazzaniga G; Panzer-Grümayer R; van der Velden V; Fischer S; Stanulla M; Basso G; Niggli FK; Schäfer BW; Sutton R; Koehler R; Zimmermann M; Valsecchi MG; Gadner H; Masera G; Schrappe M; van Dongen JJ; Biondi A; Bartram CR;
    Leukemia; 2008 Apr; 22(4):771-82. PubMed ID: 18239620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols.
    Cario G; Leoni V; Conter V; Attarbaschi A; Zaliova M; Sramkova L; Cazzaniga G; Fazio G; Sutton R; Elitzur S; Izraeli S; Lauten M; Locatelli F; Basso G; Buldini B; Bergmann AK; Lentes J; Steinemann D; Göhring G; Schlegelberger B; Haas OA; Schewe D; Buchmann S; Moericke A; White D; Revesz T; Stanulla M; Mann G; Bodmer N; Arad-Cohen N; Zuna J; Valsecchi MG; Zimmermann M; Schrappe M; Biondi A
    Haematologica; 2020 Jul; 105(7):1887-1894. PubMed ID: 31601692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency and prognostic impact of PAX5 p.P80R in pediatric acute lymphoblastic leukemia patients treated on an AIEOP-BFM acute lymphoblastic leukemia protocol.
    Jung M; Schieck M; Hofmann W; Tauscher M; Lentes J; Bergmann A; Stelter M; Möricke A; Alten J; Schlegelberger B; Schrappe M; Zimmermann M; Stanulla M; Cario G; Steinemann D
    Genes Chromosomes Cancer; 2020 Nov; 59(11):667-671. PubMed ID: 32592278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.
    Bader P; Kreyenberg H; Henze GH; Eckert C; Reising M; Willasch A; Barth A; Borkhardt A; Peters C; Handgretinger R; Sykora KW; Holter W; Kabisch H; Klingebiel T; von Stackelberg A;
    J Clin Oncol; 2009 Jan; 27(3):377-84. PubMed ID: 19064980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002.
    Stary J; Zimmermann M; Campbell M; Castillo L; Dibar E; Donska S; Gonzalez A; Izraeli S; Janic D; Jazbec J; Konja J; Kaiserova E; Kowalczyk J; Kovacs G; Li CK; Magyarosy E; Popa A; Stark B; Jabali Y; Trka J; Hrusak O; Riehm H; Masera G; Schrappe M
    J Clin Oncol; 2014 Jan; 32(3):174-84. PubMed ID: 24344215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of protracted high-dose L-asparaginase given as a second exposure in a Berlin-Frankfurt-Münster-based treatment: results of the randomized 9102 intermediate-risk childhood acute lymphoblastic leukemia study--a report from the Associazione Italiana Ematologia Oncologia Pediatrica.
    Rizzari C; Valsecchi MG; Aricò M; Conter V; Testi A; Barisone E; Casale F; Lo Nigro L; Rondelli R; Basso G; Santoro N; Masera G;
    J Clin Oncol; 2001 Mar; 19(5):1297-303. PubMed ID: 11230471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000.
    Möricke A; Zimmermann M; Valsecchi MG; Stanulla M; Biondi A; Mann G; Locatelli F; Cazzaniga G; Niggli F; Aricò M; Bartram CR; Attarbaschi A; Silvestri D; Beier R; Basso G; Ratei R; Kulozik AE; Lo Nigro L; Kremens B; Greiner J; Parasole R; Harbott J; Caruso R; von Stackelberg A; Barisone E; Rössig C; Conter V; Schrappe M
    Blood; 2016 Apr; 127(17):2101-12. PubMed ID: 26888258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group.
    Biondi A; Valsecchi MG; Seriu T; D'Aniello E; Willemse MJ; Fasching K; Pannunzio A; Gadner H; Schrappe M; Kamps WA; Bartram CR; van Dongen JJ; Panzer-Grümayer ER
    Leukemia; 2000 Nov; 14(11):1939-43. PubMed ID: 11069029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flow-cytometric minimal residual disease monitoring in blood predicts relapse risk in pediatric B-cell precursor acute lymphoblastic leukemia in trial AIEOP-BFM-ALL 2000.
    Schumich A; Maurer-Granofszky M; Attarbaschi A; Pötschger U; Buldini B; Gaipa G; Karawajew L; Printz D; Ratei R; Conter V; Schrappe M; Mann G; Basso G; Dworzak MN;
    Pediatr Blood Cancer; 2019 May; 66(5):e27590. PubMed ID: 30561169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.